{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:52:04Z","timestamp":1788871924877,"version":"build-2803163510"},"reference-count":29,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,4,25]],"date-time":"2014-04-25T00:00:00Z","timestamp":1398384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Millennium Inc","award":["Research grant"],"award-info":[{"award-number":["Research grant"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2014,8]]},"abstract":"Summary<\/jats:title>\n \n There is a lack of published data examining non\u2010cytotoxic options for the frontline treatment of patients with high\u2010tumour burden (\n HTB<\/jats:styled-content>\n ) indolent non\u2010Hodgkin lymphoma (\n iNHL<\/jats:styled-content>\n ). We completed a multicentre phase II study for patients with untreated\n HTB iNHL<\/jats:styled-content>\n (\n NCT<\/jats:styled-content>\n 00369707) consisting of three induction cycles of weekly bortezomib and rituximab followed by an abbreviated consolidation. Forty\u2010two patients were treated and all were evaluable; the most common histology was follicular lymphoma (\n FL<\/jats:styled-content>\n ) (\n n<\/jats:italic>\n \u00a0=\u00a033, 79%). Patient characteristics included median age 62\u00a0years (40\u201386); 38% bulky disease; 19% malignant effusions; 91% advanced\u2010stage disease; and median\n FL<\/jats:styled-content>\n International Prognostic Index (\n FLIPI<\/jats:styled-content>\n ) score was 3. Therapy was well tolerated with few grade 3\/4 toxicities including minimal neurotoxicity. On intent\u2010to\u2010treat, the overall response rate (\n ORR<\/jats:styled-content>\n ) at end of therapy was 70% with a complete remission (\n CR<\/jats:styled-content>\n ) rate of 40% (\n FL<\/jats:styled-content>\n :\n ORR<\/jats:styled-content>\n 76%,\n CR<\/jats:styled-content>\n 44%). With 50\u2010month median follow\u2010up, 4\u2010year progression\u2010free survival (\n PFS<\/jats:styled-content>\n ) was 44% with 4\u2010year overall survival (\n OS<\/jats:styled-content>\n ) of 87% (\n FL<\/jats:styled-content>\n : 44% and 97%, respectively). Four\u2010year\n PFS<\/jats:styled-content>\n for\n FLIPI<\/jats:styled-content>\n 0\u20132 vs. 3\u20135 was 60% vs. 26% respectively (\n P\u00a0<\/jats:italic>\n =\n \u00a0<\/jats:italic>\n 0\u00b702), with corresponding\n OS<\/jats:styled-content>\n rates of 92% and 81% respectively (\n P\u00a0<\/jats:italic>\n =\n \u00a0<\/jats:italic>\n 0\u00b716). Collectively, bortezomib\/rituximab is a non\u2010cytotoxic therapeutic regimen that was well tolerated and resulted in long\u2010term survival rates approximating prior rituximab\/cytotoxic chemotherapy series for untreated\n HTB FL<\/jats:styled-content>\n .\n <\/jats:p>","DOI":"10.1111\/bjh.12915","type":"journal-article","created":{"date-parts":[[2014,4,25]],"date-time":"2014-04-25T02:31:01Z","timestamp":1398393061000},"page":"514-520","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non\u2010Hodgkin lymphoma: a multicentre phase\n II<\/scp>\n study"],"prefix":"10.1111","volume":"166","author":[{"given":"Andrew M.","family":"Evens","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology Tufts Medical Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell R.","family":"Smith","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[{"name":"Division of Hematology\u2010Oncology Department of Medicine Sylvester Comprehensive Cancer Center University of Miami School of Medicine Miami FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Helenowski","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine Northwestern University Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Millenson","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane N.","family":"Winter","sequence":"additional","affiliation":[{"name":"Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center Northwestern University Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve T.","family":"Rosen","sequence":"additional","affiliation":[{"name":"Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center Northwestern University Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo I.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center Northwestern University Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,4,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14110-4"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.082412"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1110"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70150-4"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3069"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.1.101"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-233155"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.0866"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.1844"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-314708"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3411"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.674"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.4618"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_7_17_1","doi-asserted-by":"crossref","first-page":"3420a","DOI":"10.1182\/blood.V110.11.3420.3420","article-title":"Preliminary pharmacokinetic (PK) analysis of Eastern Cooperative Oncology Group Protocol E4402: Rituximab Extended Schedule or Re\u2010Treatment Trial (RESORT)","volume":"110","author":"Kahl B.S.","year":"2007","journal-title":"Blood"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.4786"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2647"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12198"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.11.015"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-153189"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.6594"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.7.2332"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.7980"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12915","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12915","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T17:49:21Z","timestamp":1696268961000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,25]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.1111\/bjh.12915"],"URL":"https:\/\/doi.org\/10.1111\/bjh.12915","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,25]]},"assertion":[{"value":"2014-02-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-03-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-04-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}